NeuroPace (NPCE) delivered earnings and revenue surprises of +50.00% and -14.59%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
This is the newest page. Registered accounts read further back.